174 related articles for article (PubMed ID: 35583604)
21. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
[TBL] [Abstract][Full Text] [Related]
22. [Development of novel cereblon modulators and their target molecules].
Ito T
Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
[TBL] [Abstract][Full Text] [Related]
23. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4
Read KA; Powell MD; Baker CE; Sreekumar BK; Ringel-Scaia VM; Bachus H; Martin RE; Cooley ID; Allen IC; Ballesteros-Tato A; Oestreich KJ
J Immunol; 2017 Oct; 199(7):2377-2387. PubMed ID: 28848064
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide Stabilizes Protein-Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions.
Miñarro-Lleonar M; Bertran-Mostazo A; Duro J; Barril X; Juárez-Jiménez J
J Med Chem; 2023 May; 66(9):6037-6046. PubMed ID: 37083375
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
26. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity.
Koipally J; Georgopoulos K
J Biol Chem; 2000 Jun; 275(26):19594-602. PubMed ID: 10766745
[TBL] [Abstract][Full Text] [Related]
27. Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation.
Mazzurana L; Forkel M; Rao A; Van Acker A; Kokkinou E; Ichiya T; Almer S; Höög C; Friberg D; Mjösberg J
Eur J Immunol; 2019 Sep; 49(9):1344-1355. PubMed ID: 31151137
[TBL] [Abstract][Full Text] [Related]
28. Critical function of Ikaros in controlling Aiolos gene expression.
Ghadiri A; Duhamel M; Fleischer A; Reimann A; Dessauge F; Rebollo A
FEBS Lett; 2007 Apr; 581(8):1605-16. PubMed ID: 17383641
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Ikaros family splicing variants in human hematopoietic lineages.
Matulić M; Paradzik M; Puskarić BJ; Stipić J; Antica M
Coll Antropol; 2010 Mar; 34(1):59-62. PubMed ID: 20432734
[TBL] [Abstract][Full Text] [Related]
30. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
31. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.
Mo Z; Wood S; Namiranian S; Mizukoshi R; Weng S; Jang IS; Fontanillo C; Baughman JM; Silva-Torres A; Slade M; Khater M; Wang K; Rolfe M; Lu G
Blood Adv; 2021 Apr; 5(7):2027-2039. PubMed ID: 33847741
[TBL] [Abstract][Full Text] [Related]
32. Protein Degradation via CRL4
Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
[TBL] [Abstract][Full Text] [Related]
33. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
35. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
[TBL] [Abstract][Full Text] [Related]
36. The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma.
Wang B; Duan J; Zhou L
Anticancer Drugs; 2021 Mar; 32(3):227-232. PubMed ID: 33534410
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
38. The IKAROS interaction with a complex including chromatin remodeling and transcription elongation activities is required for hematopoiesis.
Bottardi S; Mavoungou L; Pak H; Daou S; Bourgoin V; Lakehal YA; Affar el B; Milot E
PLoS Genet; 2014 Dec; 10(12):e1004827. PubMed ID: 25474253
[TBL] [Abstract][Full Text] [Related]
39. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
40. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
